Three Scalable Growth Plays in Healthcare Technology

The setup for scalable healthcare technology growth is now defined by a powerful convergence of capital, regulation, and technological velocity. This is not the speculative bubble of a decade ago, but a disciplined, AI-native expansion where the winners are rapidly scaling into mission-critical infrastructure.

First, the capital markets have reopened with a new set of rules. After a two-year drought, the IPO window swung wide in 2024 and 2025, with six health tech companies raising $36.6 billion in fresh market capitalization. Crucially, this second generation-firms like Waystar and Tempus-brought strong unit economics and clear paths to profitability, a stark contrast to the hype-driven firms of the last cycle. Their public market performance was robust, with new health tech stocks rising 18% in 2025, matching the broader indices. This signals that patient capital is returning, but it is demanding financial discipline.

That discipline is being rewarded in the private market, where a stark divide is emerging. U.S. digital health funding surged to $14.2 billion in 2025, a 35% jump from the prior year. Yet this growth is highly concentrated. The capital is flowing overwhelmingly to AI-native upstarts that can demonstrate rapid scaling, while many others struggle. This is creating a winner-take-most dynamic, where a handful of well-funded companies are gaining significant market influence, forcing a jockeying for position among both new breakouts and established incumbents.

The regulatory tailwind is accelerating this shift. The FDA has become a key enabler, with 235 AI-enabled device approvals in 2024 alone-the most in the agency's history. This isn't just about new gadgets; it's about embedding AI into core clinical workflows. As these technologies move from workflow tools to essential infrastructure, they drive both revenue growth and margin expansion. The result is a sector where companies are hitting $100 million in annual recurring revenue in under five years, a velocity that rivals the fastest software companies.

The bottom line is a market in consolidation. The capital, the regulatory approval, and the technological leap are all aligning to scale a new class of financially sound, AI-native firms. For investors, the opportunity is to identify those companies positioned to become the indispensable platforms within this evolving healthcare ecosystem.

The Scalability of a Digital Health Platform

The growth thesis for healthcare technology is now grounded in a massive, expanding market. The global healthcare IT sector, valued at $663 billion in 2023, is projected to balloon to $1.8 trillion by 2030, growing at a compound rate of 15.8%. This isn't just a large market; it's a structural shift where technology moves from a support function to essential infrastructure. For a digital health platform, this represents a clear path to dominance.

Success in this new era is narrowing to high-impact areas that solve acute provider pain. The focus is no longer on novel gadgets but on automating the core administrative burden. As the sector shifts from adoption to endurance, the most valuable applications are those that cut off documentation burden and quicken reviews. Platforms that streamline medical coding and billing directly address the operational efficiency crisis facing healthcare systems, turning a cost center into a lever for margin expansion. This is where scalability meets necessity.

The financial discipline of the new generation of health tech companies is what truly sets them apart. Unlike the hype-driven firms of the past, today's leaders combine rapid growth with sound unit economics. Evidence shows that this second wave-companies like Waystar and Tempus-has revenue growth and FCF margin of high-growth software counterparts. They are hitting $100 million in annual recurring revenue in under five years, a velocity that rivals the fastest software companies. This financial rigor, paired with a clear path to profitability, is what attracts patient capital and justifies their premium on the balance sheet.

The bottom line is that a digital health platform operating in this high-impact, high-growth segment has a powerful moat. It's built on a massive and expanding TAM, a solution to a critical industry pain point, and a business model that scales efficiently. For the growth investor, this is the trifecta: a large market, a defensible product, and a proven ability to execute.

Company 2: AI-Enabled Medical Device Leader

The medical device sector is undergoing a transformation where AI is no longer a feature but a fundamental driver of growth and market leadership. The global market, valued at nearly $680 billion, is projected to more than double to over $1.1 trillion by 2034. Within this expansion, AI integration is a key lever for premium pricing and market share gains, turning established players into indispensable partners for healthcare providers.

Leadership in this new era is being defined by regulatory momentum and a robust innovation pipeline. The FDA has become a critical enabler, with 235 AI-enabled device approvals in 2024 alone-the most in the agency's history. This record pace signals a clear regulatory tailwind for companies that can demonstrate clinical value and safety. For a company like Abbott, which operates in high-growth segments like continuous glucose monitoring with its FreeStyle Libre, this creates a powerful feedback loop. Each new FDA clearance for an AI-enhanced device validates its technology, strengthens its brand, and opens new revenue streams within its existing customer base.

The financial advantage of being a leader is also becoming more pronounced. The capital markets are rewarding proven scale and innovation, with mega funds playing a decisive role. While the evidence points to a broader trend in digital health, the concentration of capital is clear: 2025 saw $14.2B in venture funding for U.S. digital health startups, with a handful of companies attracting the largest rounds. This creates a capital advantage for established players who can leverage their balance sheets to acquire promising AI startups or fund internal R&D at a pace that smaller competitors cannot match. For a company with Abbott's diversified portfolio and strong cash flow, this means it can aggressively defend its core franchises while building a moat around its next-generation AI devices.

The bottom line for the growth investor is that AI is accelerating the consolidation of the medtech landscape. The combination of a massive, expanding TAM, a regulatory environment that clears the path for innovation, and a capital structure that favors the well-funded creates a powerful setup. Companies that can demonstrate a continuous pipeline of FDA-approved AI enhancements are positioned not just to grow with the market, but to capture a disproportionate share of its future value.

Catalysts, Risks, and What to Watch

The growth thesis for healthcare technology hinges on a few clear catalysts and a significant risk. For investors, the near term is about watching whether these forces play out as expected.

The most direct catalyst is regulatory momentum. The FDA's record pace of approvals is a powerful signal. With 235 AI-enabled device approvals in 2024 alone, the agency is actively clearing the path for innovation. This isn't just about new gadgets; it's about validating the commercial viability of AI-native platforms. The key metric to watch is the continued acceleration of these approvals, particularly for devices that move AI from back-office automation into real patient care-like diagnostic tools or surgical robots. Each new clearance de-risks the technology for providers and opens a new revenue stream, directly fueling growth.

Mergers and acquisitions are the other major catalyst, acting as a powerful driver of consolidation. The evidence shows this trend is already accelerating. In 2025, the sector saw a notable increase in deal activity, including a number of distressed exits. This signals that capital is being used to resolve uncertainty and build scale. For the growth investor, the critical metric is the pace and nature of these deals. Are mega funds and well-capitalized incumbents using their balance sheets to acquire promising AI startups, thereby accelerating their own product pipelines? Or are smaller players being forced into partnerships or sales to survive? The winners will be those that can integrate these acquisitions to expand their market influence.

The primary risk is a bifurcation in funding that could leave many companies stranded. The capital is concentrated, with 2025 seeing $14.2 billion in venture funding for U.S. digital health startups, but that growth is highly uneven. The data reveals a stark divide: while a handful of AI-native upstarts attract huge rounds, many others are struggling. This creates a winner-take-most dynamic where companies unable to secure large funding rounds may find it impossible to compete on scale or integrate new technologies. The risk is that they get squeezed out, unable to fund the R&D or acquisitions needed to keep pace. For the growth thesis, this bifurcation is a double-edged sword-it validates the path for the winners but threatens the broader ecosystem that feeds innovation.

The bottom line is that the setup is clear. The catalysts-regulatory approval and M&A-are in motion. The risk of funding fragmentation is real. For investors, the watchlist is simple: track FDA AI device approvals, monitor the pace of strategic deals, and watch for signs of a funding gap widening between the well-backed and the rest.